InvestorsHub Logo
Followers 834
Posts 119882
Boards Moderated 17
Alias Born 09/05/2002

Re: JK2016 post# 2083

Thursday, 11/18/2021 5:36:11 PM

Thursday, November 18, 2021 5:36:11 PM

Post# of 3011
Re: ENTA EDP-721

Discontinuing a compound is always a letdown, but it’s much better to find a safety problem in phase-1 than later on.

ENTA will need to find a second oral compound to complement EDP-514 (the lead HBV compound), which could either be another RNA destabilizer or a compound with a different MoA. The company’s drug-discovery engine is up to the task, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News